D
ANI Pharmaceuticals, Inc.
ANIP
$59.16
$1.131.95%
D
Sell
11/11/2024Downgrade
ANI Pharmaceuticals, Inc. (ANIP) was downgraded to D from D+ on 11/11/2024 due to a noticeable decline in the valuation index, solvency index and efficiency index. Net income declined 956.67% from -$2.29M to -$24.17M, debt to equity increased from 0.63 to 1.54, and the quick ratio declined from 2.95 to 1.84.
ANI Pharmaceuticals, Inc. (ANIP) was downgraded to D from D+ on 11/11/2024 due to a noticeable decline in the valuation index, solvency index and efficiency index. Net income declined 956.67% from -$2.29M to -$24.17M, debt to equity increased from 0.63 to 1.54, and the quick ratio declined from 2.95 to 1.84.
D
Sell
8/7/2024Downgrade
ANI Pharmaceuticals, Inc. (ANIP) was downgraded to D+ from C on 8/7/2024 due to a significant decline in the growth index, total return index and valuation index. Earnings per share declined from $0.825 to -$0.14, EBIT declined 40.03% from $15.06M to $9.03M, and operating cash flow declined 4.68% from $18.27M to $17.41M.
ANI Pharmaceuticals, Inc. (ANIP) was downgraded to D+ from C on 8/7/2024 due to a significant decline in the growth index, total return index and valuation index. Earnings per share declined from $0.825 to -$0.14, EBIT declined 40.03% from $15.06M to $9.03M, and operating cash flow declined 4.68% from $18.27M to $17.41M.
C
Hold
6/17/2024Downgrade
ANI Pharmaceuticals, Inc. (ANIP) was downgraded to C from C+ on 6/17/2024 due to a decline in the total return index and valuation index.
ANI Pharmaceuticals, Inc. (ANIP) was downgraded to C from C+ on 6/17/2024 due to a decline in the total return index and valuation index.
C
Hold
5/21/2024Upgraded
ANI Pharmaceuticals, Inc. (ANIP) was upgraded to C+ from C on 5/21/2024 due to an increase in the valuation index, total return index and volatility index.
ANI Pharmaceuticals, Inc. (ANIP) was upgraded to C+ from C on 5/21/2024 due to an increase in the valuation index, total return index and volatility index.
C
Hold
5/14/2024Upgraded
ANI Pharmaceuticals, Inc. (ANIP) was upgraded to C from C- on 5/14/2024 due to a significant increase in the growth index, total return index and valuation index. Earnings per share increased from $0.0365 to $0.825, EBIT increased 72.83% from $8.71M to $15.06M, and total revenue increased 4.39% from $131.65M to $137.43M.
ANI Pharmaceuticals, Inc. (ANIP) was upgraded to C from C- on 5/14/2024 due to a significant increase in the growth index, total return index and valuation index. Earnings per share increased from $0.0365 to $0.825, EBIT increased 72.83% from $8.71M to $15.06M, and total revenue increased 4.39% from $131.65M to $137.43M.
C
Hold
3/18/2024Upgraded
ANI Pharmaceuticals, Inc. (ANIP) was upgraded to C- from D+ on 3/18/2024 due to an increase in the total return index, solvency index and volatility index.
ANI Pharmaceuticals, Inc. (ANIP) was upgraded to C- from D+ on 3/18/2024 due to an increase in the total return index, solvency index and volatility index.
D
Sell
3/1/2024Downgrade
ANI Pharmaceuticals, Inc. (ANIP) was downgraded to D+ from C on 3/1/2024 due to a significant decline in the growth index, total return index and solvency index. Earnings per share declined from $0.4524 to $0.0365, EBIT declined 43.41% from $15.39M to $8.71M, and the quick ratio declined from 2.77 to 2.63.
ANI Pharmaceuticals, Inc. (ANIP) was downgraded to D+ from C on 3/1/2024 due to a significant decline in the growth index, total return index and solvency index. Earnings per share declined from $0.4524 to $0.0365, EBIT declined 43.41% from $15.39M to $8.71M, and the quick ratio declined from 2.77 to 2.63.
C
Hold
1/4/2024Upgraded
ANI Pharmaceuticals, Inc. (ANIP) was upgraded to C from D- on 1/4/2024 due to a significant increase in the growth index, efficiency index and solvency index. Net income increased 59.17% from $6.25M to $9.94M, earnings per share increased from $0.29 to $0.4524, and operating cash flow increased 55.96% from $20.63M to $32.17M.
ANI Pharmaceuticals, Inc. (ANIP) was upgraded to C from D- on 1/4/2024 due to a significant increase in the growth index, efficiency index and solvency index. Net income increased 59.17% from $6.25M to $9.94M, earnings per share increased from $0.29 to $0.4524, and operating cash flow increased 55.96% from $20.63M to $32.17M.
D
Sell
3/14/2023Downgrade
ANI Pharmaceuticals, Inc. (ANIP) was downgraded to D- from D+ on 3/14/2023 due to a decline in the solvency index and valuation index. The quick ratio declined from 2.41 to 2.15.
ANI Pharmaceuticals, Inc. (ANIP) was downgraded to D- from D+ on 3/14/2023 due to a decline in the solvency index and valuation index. The quick ratio declined from 2.41 to 2.15.
D
Sell
3/6/2023Upgraded
ANI Pharmaceuticals, Inc. (ANIP) was upgraded to D+ from D on 3/6/2023 due to an increase in the total return index and volatility index.
ANI Pharmaceuticals, Inc. (ANIP) was upgraded to D+ from D on 3/6/2023 due to an increase in the total return index and volatility index.
D
Sell
2/23/2023Upgraded
ANI Pharmaceuticals, Inc. (ANIP) was upgraded to D from D- on 2/23/2023 due to an increase in the volatility index, total return index and valuation index.
ANI Pharmaceuticals, Inc. (ANIP) was upgraded to D from D- on 2/23/2023 due to an increase in the volatility index, total return index and valuation index.
D
Sell
2/8/2023Downgrade
ANI Pharmaceuticals, Inc. (ANIP) was downgraded to D- from D on 2/8/2023 due to a decline in the total return index and valuation index.
ANI Pharmaceuticals, Inc. (ANIP) was downgraded to D- from D on 2/8/2023 due to a decline in the total return index and valuation index.
D
Sell
1/11/2023Downgrade
ANI Pharmaceuticals, Inc. (ANIP) was downgraded to D from D+ on 1/11/2023 due to a decline in the total return index.
ANI Pharmaceuticals, Inc. (ANIP) was downgraded to D from D+ on 1/11/2023 due to a decline in the total return index.
D
Sell
12/27/2022Upgraded
ANI Pharmaceuticals, Inc. (ANIP) was upgraded to D+ from D on 12/27/2022 due to an increase in the volatility index.
ANI Pharmaceuticals, Inc. (ANIP) was upgraded to D+ from D on 12/27/2022 due to an increase in the volatility index.
D
Sell
11/10/2022Downgrade
ANI Pharmaceuticals, Inc. (ANIP) was downgraded to D from D+ on 11/10/2022 due to a decline in the volatility index.
ANI Pharmaceuticals, Inc. (ANIP) was downgraded to D from D+ on 11/10/2022 due to a decline in the volatility index.
D
Sell
11/1/2022Upgraded
ANI Pharmaceuticals, Inc. (ANIP) was upgraded to D+ from D on 11/1/2022 due to a substantial increase in the total return index, volatility index and solvency index.
ANI Pharmaceuticals, Inc. (ANIP) was upgraded to D+ from D on 11/1/2022 due to a substantial increase in the total return index, volatility index and solvency index.
D
Sell
5/31/2022Upgraded
ANI Pharmaceuticals, Inc. (ANIP) was upgraded to D from D- on 05/31/2022.
ANI Pharmaceuticals, Inc. (ANIP) was upgraded to D from D- on 05/31/2022.
D
Sell
5/13/2022Downgrade
ANI Pharmaceuticals, Inc. (ANIP) was downgraded to D- from D on 5/13/2022 due to a noticeable decline in the solvency index, total return index and volatility index. Debt to equity increased from 0.88 to 0.9.
ANI Pharmaceuticals, Inc. (ANIP) was downgraded to D- from D on 5/13/2022 due to a noticeable decline in the solvency index, total return index and volatility index. Debt to equity increased from 0.88 to 0.9.
D
Sell
5/4/2022Upgraded
ANI Pharmaceuticals, Inc. (ANIP) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index.
ANI Pharmaceuticals, Inc. (ANIP) was upgraded to D from E+ on 5/4/2022 due to an increase in the volatility index.
E
Sell
5/3/2022Downgrade
ANI Pharmaceuticals, Inc. (ANIP) was downgraded to E+ from D- on 5/3/2022 due to a decline in the total return index and volatility index.
ANI Pharmaceuticals, Inc. (ANIP) was downgraded to E+ from D- on 5/3/2022 due to a decline in the total return index and volatility index.
D
Sell
4/20/2022Downgrade
ANI Pharmaceuticals, Inc. (ANIP) was downgraded to D- from D on 4/20/2022 due to a significant decline in the growth index, total return index and volatility index. Earnings per share declined from -$0.37 to -$1.7196, EBIT declined 242.88% from -$3.06M to -$10.5M, and operating cash flow declined 125.56% from -$5.4M to -$12.19M.
ANI Pharmaceuticals, Inc. (ANIP) was downgraded to D- from D on 4/20/2022 due to a significant decline in the growth index, total return index and volatility index. Earnings per share declined from -$0.37 to -$1.7196, EBIT declined 242.88% from -$3.06M to -$10.5M, and operating cash flow declined 125.56% from -$5.4M to -$12.19M.
D
Sell
3/7/2022Downgrade
ANI Pharmaceuticals, Inc. (ANIP) was downgraded to D from D+ on 3/7/2022 due to a decline in the volatility index and total return index.
ANI Pharmaceuticals, Inc. (ANIP) was downgraded to D from D+ on 3/7/2022 due to a decline in the volatility index and total return index.
D
Sell
12/7/2021Upgraded
ANI Pharmaceuticals, Inc. (ANIP) was upgraded to D+ from D on 12/7/2021 due to an increase in the volatility index, total return index and valuation index.
ANI Pharmaceuticals, Inc. (ANIP) was upgraded to D+ from D on 12/7/2021 due to an increase in the volatility index, total return index and valuation index.
D
Sell
11/23/2021Upgraded
ANI Pharmaceuticals, Inc. (ANIP) was upgraded to D from D- on 11/23/2021 due to an increase in the total return index, volatility index and valuation index.
ANI Pharmaceuticals, Inc. (ANIP) was upgraded to D from D- on 11/23/2021 due to an increase in the total return index, volatility index and valuation index.
D
Sell
11/8/2021Downgrade
ANI Pharmaceuticals, Inc. (ANIP) was downgraded to D- from D+ on 11/8/2021 due to a decline in the volatility index and valuation index.
ANI Pharmaceuticals, Inc. (ANIP) was downgraded to D- from D+ on 11/8/2021 due to a decline in the volatility index and valuation index.
D
Sell
11/3/2021Upgraded
ANI Pharmaceuticals, Inc. (ANIP) was upgraded to D+ from D on 11/3/2021 due to a significant increase in the growth index, total return index and volatility index. Earnings per share increased from -$1.17 to -$0.37, EBIT increased 43.85% from -$5.45M to -$3.06M, and total revenue increased 7.07% from $48.63M to $52.06M.
ANI Pharmaceuticals, Inc. (ANIP) was upgraded to D+ from D on 11/3/2021 due to a significant increase in the growth index, total return index and volatility index. Earnings per share increased from -$1.17 to -$0.37, EBIT increased 43.85% from -$5.45M to -$3.06M, and total revenue increased 7.07% from $48.63M to $52.06M.
D
Sell
5/8/2020Downgrade
ANI Pharmaceuticals, Inc. (ANIP) was downgraded to D from D+ on 5/8/2020 due to a large decline in the efficiency index, total return index and valuation index. Net income declined 45.01% from -$4.84M to -$7.01M, and total capital declined 1.01% from $405.24M to $401.14M.
ANI Pharmaceuticals, Inc. (ANIP) was downgraded to D from D+ on 5/8/2020 due to a large decline in the efficiency index, total return index and valuation index. Net income declined 45.01% from -$4.84M to -$7.01M, and total capital declined 1.01% from $405.24M to $401.14M.
D
Sell
2/28/2020Downgrade
ANI Pharmaceuticals, Inc. (ANIP) was downgraded to D+ from C on 2/28/2020 due to a significant decline in the growth index, total return index and volatility index. Earnings per share declined from $0.32 to -$0.4007, EBIT declined 162.72% from $7.33M to -$4.6M, and operating cash flow declined 77.96% from $21.79M to $4.8M.
ANI Pharmaceuticals, Inc. (ANIP) was downgraded to D+ from C on 2/28/2020 due to a significant decline in the growth index, total return index and volatility index. Earnings per share declined from $0.32 to -$0.4007, EBIT declined 162.72% from $7.33M to -$4.6M, and operating cash flow declined 77.96% from $21.79M to $4.8M.
C
Hold
8/8/2019Upgraded
ANI Pharmaceuticals, Inc. (ANIP) was upgraded to C from C- on 8/8/2019 due to a significant increase in the growth index, valuation index and efficiency index. Net income increased 1,366.59% from $449 to $6.59M, earnings per share increased from $0.0375 to $0.53, and EBIT increased 111.09% from $4.4M to $9.29M.
ANI Pharmaceuticals, Inc. (ANIP) was upgraded to C from C- on 8/8/2019 due to a significant increase in the growth index, valuation index and efficiency index. Net income increased 1,366.59% from $449 to $6.59M, earnings per share increased from $0.0375 to $0.53, and EBIT increased 111.09% from $4.4M to $9.29M.
C
Hold
7/15/2019Downgrade
ANI Pharmaceuticals, Inc. (ANIP) was downgraded to C- from C on 7/15/2019 due to a substantial decline in the growth index, valuation index and solvency index. Earnings per share declined from $0.4499 to $0.0375, EBIT declined 69.53% from $14.45M to $4.4M, and operating cash flow declined 47.52% from $27.23M to $14.29M.
ANI Pharmaceuticals, Inc. (ANIP) was downgraded to C- from C on 7/15/2019 due to a substantial decline in the growth index, valuation index and solvency index. Earnings per share declined from $0.4499 to $0.0375, EBIT declined 69.53% from $14.45M to $4.4M, and operating cash flow declined 47.52% from $27.23M to $14.29M.
C
Hold
3/4/2019Upgraded
ANI Pharmaceuticals, Inc. (ANIP) was upgraded to C from D+ on 3/4/2019 due to a significant increase in the growth index, efficiency index and valuation index. Operating cash flow increased 227.35% from $8.32M to $27.23M, EBIT increased 29.97% from $11.11M to $14.45M, and total revenue increased 12.66% from $50.7M to $57.12M.
ANI Pharmaceuticals, Inc. (ANIP) was upgraded to C from D+ on 3/4/2019 due to a significant increase in the growth index, efficiency index and valuation index. Operating cash flow increased 227.35% from $8.32M to $27.23M, EBIT increased 29.97% from $11.11M to $14.45M, and total revenue increased 12.66% from $50.7M to $57.12M.
D
Sell
3/5/2018Downgrade
ANI Pharmaceuticals, Inc. (ANIP) was downgraded to D+ from C on 3/5/2018 due to a major decline in the growth index, efficiency index and valuation index. Earnings per share declined from $0.4 to -$0.8274, net income declined 304% from $4.72M to -$9.63M, and EBIT declined 7.82% from $12.13M to $11.18M.
ANI Pharmaceuticals, Inc. (ANIP) was downgraded to D+ from C on 3/5/2018 due to a major decline in the growth index, efficiency index and valuation index. Earnings per share declined from $0.4 to -$0.8274, net income declined 304% from $4.72M to -$9.63M, and EBIT declined 7.82% from $12.13M to $11.18M.
C
Hold
11/3/2017Upgraded
ANI Pharmaceuticals, Inc. (ANIP) was upgraded to C from C- on 11/3/2017 due to an increase in the total return index, efficiency index and valuation index. Net income increased 76.05% from $2.68M to $4.72M, and total capital increased 0.95% from $330.93M to $334.09M.
ANI Pharmaceuticals, Inc. (ANIP) was upgraded to C from C- on 11/3/2017 due to an increase in the total return index, efficiency index and valuation index. Net income increased 76.05% from $2.68M to $4.72M, and total capital increased 0.95% from $330.93M to $334.09M.
C
Hold
10/13/2017Downgrade
ANI Pharmaceuticals, Inc. (ANIP) was downgraded to C- from C on 10/13/2017 due to a decline in the valuation index.
ANI Pharmaceuticals, Inc. (ANIP) was downgraded to C- from C on 10/13/2017 due to a decline in the valuation index.
C
Hold
9/28/2017Upgraded
ANI Pharmaceuticals, Inc. (ANIP) was upgraded to C from C- on 9/28/2017 due to an increase in the total return index and volatility index.
ANI Pharmaceuticals, Inc. (ANIP) was upgraded to C from C- on 9/28/2017 due to an increase in the total return index and volatility index.
C
Hold
9/13/2017Downgrade
ANI Pharmaceuticals, Inc. (ANIP) was downgraded to C- from C on 9/13/2017 due to a decline in the valuation index, solvency index and total return index.
ANI Pharmaceuticals, Inc. (ANIP) was downgraded to C- from C on 9/13/2017 due to a decline in the valuation index, solvency index and total return index.
C
Hold
8/7/2017Upgraded
ANI Pharmaceuticals, Inc. (ANIP) was upgraded to C from C- on 8/7/2017 due to a major increase in the growth index, valuation index and efficiency index. Net income increased 132.73% from $1.15M to $2.68M, earnings per share increased from $0.099 to $0.23, and total revenue increased 22.21% from $36.63M to $44.76M.
ANI Pharmaceuticals, Inc. (ANIP) was upgraded to C from C- on 8/7/2017 due to a major increase in the growth index, valuation index and efficiency index. Net income increased 132.73% from $1.15M to $2.68M, earnings per share increased from $0.099 to $0.23, and total revenue increased 22.21% from $36.63M to $44.76M.
C
Hold
3/6/2017Downgrade
ANI Pharmaceuticals, Inc. (ANIP) was downgraded to C- from C on 3/6/2017 due to a significant decline in the growth index, total return index and efficiency index. Net income declined 142.47% from $2.54M to -$1.08M, earnings per share declined from $0.22 to -$0.0927, and total revenue declined 0.83% from $38.53M to $38.21M.
ANI Pharmaceuticals, Inc. (ANIP) was downgraded to C- from C on 3/6/2017 due to a significant decline in the growth index, total return index and efficiency index. Net income declined 142.47% from $2.54M to -$1.08M, earnings per share declined from $0.22 to -$0.0927, and total revenue declined 0.83% from $38.53M to $38.21M.
C
Hold
11/4/2016Downgrade
ANI Pharmaceuticals, Inc. (ANIP) was downgraded to C from C+ on 11/4/2016 due to a large decline in the total return index.
ANI Pharmaceuticals, Inc. (ANIP) was downgraded to C from C+ on 11/4/2016 due to a large decline in the total return index.
C
Hold
9/30/2016Upgraded
ANI Pharmaceuticals, Inc. (ANIP) was upgraded to C+ from C on 9/30/2016 due to a significant increase in the total return index and volatility index.
ANI Pharmaceuticals, Inc. (ANIP) was upgraded to C+ from C on 9/30/2016 due to a significant increase in the total return index and volatility index.
C
Hold
8/5/2016Upgraded
ANI Pharmaceuticals, Inc. (ANIP) was upgraded to C from C- on 8/5/2016 due to a significant increase in the growth index, efficiency index and total return index. Total revenue increased 52.45% from $20.56M to $31.34M, EBIT increased 51.68% from $5.67M to $8.59M, and total capital increased 1.96% from $275.38M to $280.77M.
ANI Pharmaceuticals, Inc. (ANIP) was upgraded to C from C- on 8/5/2016 due to a significant increase in the growth index, efficiency index and total return index. Total revenue increased 52.45% from $20.56M to $31.34M, EBIT increased 51.68% from $5.67M to $8.59M, and total capital increased 1.96% from $275.38M to $280.77M.
C
Hold
7/7/2016Downgrade
ANI Pharmaceuticals, Inc. (ANIP) was downgraded to C- from C on 7/7/2016 due to a decline in the valuation index.
ANI Pharmaceuticals, Inc. (ANIP) was downgraded to C- from C on 7/7/2016 due to a decline in the valuation index.
C
Hold
6/22/2016Upgraded
ANI Pharmaceuticals, Inc. (ANIP) was upgraded to C from C- on 6/22/2016 due to an increase in the total return index, volatility index and valuation index.
ANI Pharmaceuticals, Inc. (ANIP) was upgraded to C from C- on 6/22/2016 due to an increase in the total return index, volatility index and valuation index.
C
Hold
6/7/2016Downgrade
ANI Pharmaceuticals, Inc. (ANIP) was downgraded to C- from C on 6/7/2016 due to a substantial decline in the valuation index, solvency index and growth index. The quick ratio declined from 15.02 to 6.18, earnings per share declined from $0.2515 to $0.1175, and EBIT declined 9.6% from $6.27M to $5.67M.
ANI Pharmaceuticals, Inc. (ANIP) was downgraded to C- from C on 6/7/2016 due to a substantial decline in the valuation index, solvency index and growth index. The quick ratio declined from 15.02 to 6.18, earnings per share declined from $0.2515 to $0.1175, and EBIT declined 9.6% from $6.27M to $5.67M.
C
Hold
3/11/2016Downgrade
ANI Pharmaceuticals, Inc. (ANIP) was downgraded to C from B- on 3/11/2016 due to a significant decline in the volatility index, growth index and valuation index. Operating cash flow declined 54.06% from $10.24M to $4.7M, earnings per share declined from $0.39 to $0.2515, and EBIT declined 25.83% from $8.45M to $6.27M.
ANI Pharmaceuticals, Inc. (ANIP) was downgraded to C from B- on 3/11/2016 due to a significant decline in the volatility index, growth index and valuation index. Operating cash flow declined 54.06% from $10.24M to $4.7M, earnings per share declined from $0.39 to $0.2515, and EBIT declined 25.83% from $8.45M to $6.27M.
B
Buy
1/4/2016Upgraded
ANI Pharmaceuticals, Inc. (ANIP) was upgraded to B- from C on 1/4/2016 due to a noticeable increase in the efficiency index and growth index. Operating cash flow increased 748.76% from $1.21M to $10.24M, net income increased 27.67% from $3.57M to $4.56M, and earnings per share increased from $0.3072 to $0.39.
ANI Pharmaceuticals, Inc. (ANIP) was upgraded to B- from C on 1/4/2016 due to a noticeable increase in the efficiency index and growth index. Operating cash flow increased 748.76% from $1.21M to $10.24M, net income increased 27.67% from $3.57M to $4.56M, and earnings per share increased from $0.3072 to $0.39.
C
Hold
10/26/2015Downgrade
ANI Pharmaceuticals, Inc. (ANIP) was downgraded to C from C+ on 10/26/2015 due to a large decline in the volatility index, solvency index and total return index.
ANI Pharmaceuticals, Inc. (ANIP) was downgraded to C from C+ on 10/26/2015 due to a large decline in the volatility index, solvency index and total return index.
C
Hold
10/1/2015Upgraded
ANI Pharmaceuticals, Inc. (ANIP) was upgraded to C+ from C on 10/1/2015 due to a substantial increase in the valuation index, growth index and volatility index. Operating cash flow increased 7.68% from $1.12M to $1.21M, and total revenue increased 3.81% from $18.8M to $19.52M.
ANI Pharmaceuticals, Inc. (ANIP) was upgraded to C+ from C on 10/1/2015 due to a substantial increase in the valuation index, growth index and volatility index. Operating cash flow increased 7.68% from $1.12M to $1.21M, and total revenue increased 3.81% from $18.8M to $19.52M.
C
Hold
7/1/2015Upgraded
ANI Pharmaceuticals, Inc. (ANIP) was upgraded to C from C- on 7/1/2015 due to an increase in the efficiency index, solvency index and valuation index. The quick ratio increased from 14.08 to 20.16, total capital increased 2.57% from $250.48M to $256.91M, and debt to equity declined from 0.79 to 0.77.
ANI Pharmaceuticals, Inc. (ANIP) was upgraded to C from C- on 7/1/2015 due to an increase in the efficiency index, solvency index and valuation index. The quick ratio increased from 14.08 to 20.16, total capital increased 2.57% from $250.48M to $256.91M, and debt to equity declined from 0.79 to 0.77.
C
Hold
4/1/2015Upgraded
ANI Pharmaceuticals, Inc. (ANIP) was upgraded to C- from D+ on 4/1/2015 due to a substantial increase in the valuation index, growth index and efficiency index. Net income increased 211.37% from $6.75M to $21.01M, earnings per share increased from $0.5895 to $1.8282, and operating cash flow increased 158.26% from $4.16M to $10.74M.
ANI Pharmaceuticals, Inc. (ANIP) was upgraded to C- from D+ on 4/1/2015 due to a substantial increase in the valuation index, growth index and efficiency index. Net income increased 211.37% from $6.75M to $21.01M, earnings per share increased from $0.5895 to $1.8282, and operating cash flow increased 158.26% from $4.16M to $10.74M.
D
Sell
1/2/2015Upgraded
ANI Pharmaceuticals, Inc. (ANIP) was upgraded to D+ from D on 1/2/2015 due to a significant increase in the growth index, volatility index and total return index. Total revenue increased 161.58% from $6.65M to $17.39M, and operating cash flow increased 112.85% from $1.95M to $4.16M.
ANI Pharmaceuticals, Inc. (ANIP) was upgraded to D+ from D on 1/2/2015 due to a significant increase in the growth index, volatility index and total return index. Total revenue increased 161.58% from $6.65M to $17.39M, and operating cash flow increased 112.85% from $1.95M to $4.16M.
D
Sell
7/1/2014Upgraded
ANI Pharmaceuticals, Inc. (ANIP) was upgraded to D from D- on 7/1/2014 due to a noticeable increase in the efficiency index, solvency index and valuation index. Total capital increased 124.82% from $40.96M to $92.09M, and the quick ratio increased from 6.68 to 13.66.
ANI Pharmaceuticals, Inc. (ANIP) was upgraded to D from D- on 7/1/2014 due to a noticeable increase in the efficiency index, solvency index and valuation index. Total capital increased 124.82% from $40.96M to $92.09M, and the quick ratio increased from 6.68 to 13.66.
D
Sell
3/3/2014Upgraded
ANI Pharmaceuticals, Inc. (ANIP) was upgraded to D- from E+ on 3/3/2014 due to an increase in stability, solvency and total return.
ANI Pharmaceuticals, Inc. (ANIP) was upgraded to D- from E+ on 3/3/2014 due to an increase in stability, solvency and total return.
NASDAQ
12/10/2024 4:00PM Eastern
Quotes delayed
